Ironwood Pharmaceuticals (IRWD) Net Margin (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Net Margin across 17 years of filings, most recently posting 38.28% for Q1 2026.

• Net Margin for Q1 2026 came in at 38.28%, up 12912.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5.02% (up 3631.0% YoY), and the FY2025 annual result was 32.53%, down 460.0% from the prior year.
• Net Margin came in at 38.28% for Q1 2026 at Ironwood Pharmaceuticals, up from 257.04% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 46.32% in Q3 2022 to a low of 1014.62% in Q2 2023.
• The 5-year median for Net Margin is 12.25% (2023), against an average of 78.89%.
• Across the five-year window, Net Margin plunged 105276 bps in 2023 and jumped 101375 bps in 2024, its largest moves.
• Ironwood Pharmaceuticals' Net Margin stood at 45.59% in 2022, then tumbled by 526 bps to 194.19% in 2023, then jumped by 45 bps to 106.87% in 2024, then tumbled by 141 bps to 257.04% in 2025, then soared by 115 bps to 38.28% in 2026.
• The last three Net Margin figures came in at 38.28% (Q1 2026), 257.04% (Q4 2025), and 32.84% (Q3 2025), per Business Quant data.